Introduction

Influenza A viruses (IAVs) are highly contagious viral pathogens that have been isolated from a wide variety of animals such as birds, humans, pigs, horses, dogs, cats, and marine mammals [1]. Because of their high impact on both human and animal health, IAVs have become a matter of great concern to public health authorities garnering increased scientific interest over the past decade. The increased availability of genomic information on IAVs and greatly advanced molecular techniques have provided major advances in genetically engineered influenza vaccine development, such as recombinant subunit vaccines, virus-like particles (VLPs), DNA vaccines, and vector-based vaccines. The use of such vaccines against animal influenza viruses is being actively explored in laboratory studies. These vaccines provide numerous advantages over the use of conventional inactivated whole-virus vaccines, including ease of production, immunogenicity, safety, and multivalency [2]. However, successfully translating these recent advances into the development of veterinary vaccines continues to be impeded by gaps in our understanding of differences between the goals of veterinary and human vaccines. In the past few years, several influenza VLP vaccines have been developed for veterinary use [3-8]. This review aims to give an overview of the most important results of these research efforts, and provides information about the progress and hurdles in the development of influenza VLP vaccines for veterinary use.

Virus-like particles (VLPs), which resemble infectious virus particles in structure and morphology, have been proposed to provide a new generation of vaccine candidates against various viral infections. As effective immunogens, characterized by high immunogenicity and safety, VLPs have been employed in the development of human influenza vaccines. Recently, several influenza VLP vaccines have been developed for veterinary use and successfully evaluated in swine, canine, duck, and chicken models. These VLP vaccine candidates induced protective immune responses and enabled serological differentiation between vaccinated and infected animals in conjunction with a diagnostic test. Here, we review the current progress of influenza VLP development as a next-generation vaccine technology in the veterinary field and discuss the challenges and future direction of this technology.

Keywords: Influenza, Vaccines, Virus-like particle, Veterinary
Influenza Virus in Animals

The IAV genome consists of 8 segments of single-stranded RNA, each of which encodes a different polypeptide including 2 surface glycoproteins (hemagglutinin [HA] and neuraminidase [NA]), nucleoprotein (NP), 3 polymerase proteins (polymerase basic 2, polymerase basic 1 and polymerase acidic), 2 matrix proteins (M1 and M2), and 2 nonstructural proteins (NS1 and NS2) [9]. IAVs are classified into subtypes based on the antigenic differences between their 2 surface glycoproteins, HA and NA. Sixteen HA subtypes (H1 to H16) and 9 NA subtypes (N1 to N9) have been identified among IAVs. All subtypes identified to date have been isolated from birds. The matrix protein surrounding the genome complex is enveloped in a lipid membrane covered by HA and NA. These surface antigens play an important role in protective immunity [10].

The pathogenicity of viruses in poultry species determines whether the virus is classified as low pathogenic avian influenza (LPAI) or highly pathogenic avian influenza (HPAI). HPAI has traditionally comprised either H5 or H7 subtypes [11]. The diseases caused by different avian influenza viruses (AIVs) vary in severity from causing high mortality to producing very mild forms or even inapparent infections. Sign of HPAI infection in Galliformes birds is the sudden onset of high flock mortality, which may approach 100% within a few days. LPAI viruses may cause mild-to-moderate clinical signs such as respiratory disease, depression, a reduction in egg production, and slightly elevated mortality. To prevent or eradicate AIV outbreaks, several strategies have been applied, including a high level of biosafety, movement control, stamping out, and vaccination [12]. Current vaccines against AIVs, when selected properly and administered correctly, can provide protection against clinical signs and mortality, reduce the levels and duration of virus shedding, and increase serum antibody levels, the elevation of which provides resistance against infection by raising the minimum infectious dose. Although vaccination against AIV in poultry is still a controversial topic and has been discouraged in the past, it has also been recommended as an alternative AIV control strategy [13]. From 2002 to 2010, more than 113 billion doses of AIV vaccine have been used in poultry: 95.5% as oil-emulsified, inactivated whole-AIV vaccines and 4.5% as live-vectored vaccines. The majority of vaccines have been used in the 4 H5N1 HPAI enzootic countries (China, 91%; Egypt, 4.7%; Indonesia, 2.3%; and Vietnam, 1.4%) where vaccination programs have been directed to all poultry [14]. In addition, due to the prevalence and zoonotic potential of the H9N2 viruses, an oil-based inactivated H9N2 LPAI vaccine was employed in the poultry industry in several countries [15-17].

In mammals, swine influenza virus (SIV) is not only an important respiratory pathogen in pigs but also a potential threat to human health. Swine influenza is an acute and highly contagious respiratory disease caused by IAVs subtype H1N1, H1N2, or H3N2 [18]. Since porcine respiratory epithelial cells possess receptors for both avian and human influenza viruses, pigs are thought to be the “mixing vessels” that generate new recombinant strains [19]. The outbreak of the 2009 influenza pandemic underscored the important role of pigs in the evolution and emergence of pandemic influenza viruses. Thus, the control and prevention of SIV in pigs is required for both human and animal health. To control swine influenza, vaccination is the most common practice in swine industry. Current swine influenza vaccines are adjuvanted, inactivated, whole-virus vaccines prepared typically from viruses propagated in embryonated chicken eggs [20].

Dogs are susceptible to natural influenza virus infections via transmission from avian (H3N2 and H5N1), equine (H3N8), or human (pandemic H1N1/2009 and H3N2) virus reservoirs [21-24]. Historically, dogs were not considered natural hosts for the influenza virus. However, beginning in 2004, an equine-origin H3N8 influenza virus was first isolated from racing dogs affected with acute respiratory disease in the United States [25]. Subsequent outbreaks were reported, and the canine influenza virus (CIV) H3N8 spread rapidly across the United States. Avian-origin CIV H3N2 was reported from clinically ill dogs in southern China in 2006 and 2007 [26]. In addition, an outbreak of avian-origin CIV H3N2 in pet dogs occurred in South Korea in 2007 [27]. In beagles, experimental avian-origin CIV H3N2 infection causes mortality and clinical signs such as high fever, depression, and respiratory signs [28]. In the United States and South Korea, inactivated vaccines against equine-origin CIV H3N8 (Intervet/Schering-Plough Animal Health, Elkhorn, NE, USA) and avian-origin CIV H3N2 (Green Cross Veterinary Products Co., Yongin, Korea) have been developed and were licensed in 2009 [29,30].

Influenza VLP Vaccines

Current human influenza vaccines contain soluble forms of the viral surface split antigens produced by treating chemically inactivated virus with detergent. In addition, a live-at-
tenuated influenza vaccine, FluMist (MedImmune), is licensed for intranasal delivery in humans [31]. VLPs, which resemble infectious virus particles in structure and morphology and have multiple antigenic epitopes, have been proposed as a new generation of vaccine candidates against various viral infections (Fig. 1). Influenza VLPs have been developed as non–egg-based, cell culture-derived vaccine candidates against influenza infection [32]. Influenza VLP vaccines containing influenza HA and NA antigens are produced easily in insect or mammalian cells via the simultaneous expression of HA and NA along with a viral core protein such as influenza M1 [33]. VLPs do not have viral genomes and therefore have a solid safety profile. The highly organized form of antigens on VLPs can induce strong B-cell responses [34]. The protective mechanisms of influenza VLP vaccines, that is, induction of neutralizing antibodies and HA inhibition, are similar to those of commercial influenza vaccines [32]. In addition, VLPs can stimulate antigen presentation cells and induce CD4 T-cell proliferation and cytotoxic T-cell immune responses and thus induce both B- and T-cell responses [35,36]. However, VLPs are less effective than live-attenuated vaccines at inducing cytotoxic CD8 T-cell and helper CD4 T-cell responses, as VLPs do not replicate [34]. To enhance the immunogenicity and protective efficacy of VLPs, Wang et al. [37] incorporated a membrane-anchored form of the Toll-like receptor (TLR) 5 ligand flagellin into VLPs. The results demonstrated that flagellin-containing VLPs enhanced humoral and specific cellular responses.

Several animal viruses have been investigated as candidates for the development of VLP-based vaccines for veterinary use. For mammalian species, the bluetongue virus, canine parvovirus, equine rhinitis A virus, foot and mouth disease virus, feline calicivirus, influenza virus, porcine circovirus type-2, papillomavirus, porcine encephalomyocarditis virus, porcine parvovirus, Rift valley fever virus, rotavirus, rabbi hemorrhagic disease virus, and mink enteritis virus have been investigated. For poultry species, the chicken anemia virus, goose parvovirus, infectious bursal disease virus, influenza virus, Muscovy duck parvovirus, and Newcastle disease virus (NDV) have been examined, and for fish species, the nervous necrosis virus has been studied [38,39]. In particular, several influenza VLPs have been developed and suggested as vaccine candidates for animal use, including VLPs for AIV subtype H5N3 and H9N2, HPAI H5N1, SIV H1N1, and CIV H3N2 (Table 1). All of the influenza VLPs for veterinary use have been produced using baculovirus/insect cell technology (mainly because of the high expression levels of insect cell expression systems in comparison to mammalian cell expression systems) and emulsified with an oil adjuvant. Prel et al. [6,40] developed an AIV H5N3 VLP vaccine and evaluated in Muscovy ducks. Lee et al. [3,4] developed CIV H3 VLP and LPAI H9 vaccines and evaluated in beagles and SPF chickens, respectively. The LPAI H9 and CIV H3 VLP vaccines contain HA and M1 but not NA. A single dose of vaccination with these VLP vaccines induced high antibody titers and lessened viral shedding. Park et al. [5] developed an HPAI H5N1 VLP vaccine without purification step and evaluated in SPF

---

**Table 1. Influenza virus-like particles as candidate vaccines for veterinary use**

| Virus                  | Composition       | Animal                  | Adjuvant         | Expression system | Purification                  | References          |
|------------------------|-------------------|-------------------------|------------------|------------------|------------------------------|---------------------|
| Avian influenza H5N3   | HA, NA, M1        | SPF muscovy duck        | Oil-emulsion     | Baculovirus (Sf9) | Sucrose density gradient     | Prel et al. [2008]  |
| Avian influenza H9N2   | HA, M1            | SPF chicken             | Oil-emulsion     | Baculovirus (Sf9) | Sucrose density gradient     | Lee et al. [2011]   |
| Pandemic H1N1          | HA, NA, M1        | Influenza free pigs     | Oil emulsion     | Baculovirus (Sf9) | Sucrose density gradient     | Pyo et al. [2012]   |
| Avian influenza H5N1   | HA, NA, M1        | SPF chicken             | Oil emulsion     | Baculovirus (Sf9) | -                            | Park et al. [2013]  |
| Canine influenza H3N2  | HA, M1            | SPF beagle dog          | Oil-emulsion     | Baculovirus (Sf9) | Sucrose density gradient     | Lee et al. [2013]   |

---

**Fig. 1.** Schematic diagrams of influenza virus-like particles (VLP). (A) Influenza VLP containing matrix protein M1 and hemagglutinin (HA). (B) Influenza VLP containing HA, neuraminidase (NA), and matrix protein M1. (C) Chimeric influenza VLP containing matrix protein M1, HA, and flagellin as molecular adjuvant. (D) Chimeric influenza VLP containing matrix protein M1, HA, and foreign antigens.
Vaccination in veterinary fields has greatly improved animal health, welfare, productivity of industry animals, and eventually contributed to food safety [2]. In particular, vaccination has been proven to be a cost-effective measure for the prevention and eradication of infectious diseases. Additionally, veterinary vaccines have already made enormous impacts not only on veterinary fields but also on public health. The major goals of vaccination for industry animals are significantly different from those for human vaccination. The ultimate goals of veterinary vaccines are to improve the health and welfare of companion animals, increase production of livestock in a cost-effective manner, and prevent zoonotic infection. The final successful outcome of vaccine development in the veterinary field is the generation of a product that will be available in the marketplace at a reasonable cost or that will be used in the field to achieve desired outcomes [42].

With livestock animals, there is a considerable focus on the direct and indirect costs of vaccines. Vaccine production cost has been thought to be an important issue that influences the feasibility of recombinant subunit vaccines including VLP for veterinary use. In terms of the manufacturing advantages of VLPs, HPAI VLP vaccines have potential advantages over egg-based inactivated influenza vaccines because VLPs can be produced without the need for expensive biocontainment facilities, which are required for the propagation of HPAI strains in vaccine production. Sucrose density gradient purification using ultracentrifugation is a popular method for purifying cell-assembled VLPs in most laboratories (Table 1). However, this procedure is not economically scalable. To reduce the production cost of VLP vaccines, Park et al. [5] developed a H5N1 VLP vaccine that was prepared without using expensive and time-consuming purification procedures (aside from low centrifugation to remove large cell debris). The use of crude, unpurified VLPs could be a promising method for decreasing the production cost of VLP vaccines for veterinary use. However, these crude VLPs may contain high titers of baculovirus and insect cell derived proteins. Although baculovirus is known to be essentially nonpathogenic to mammals [43], baculovirus contamination may contribute to the overall immunogenicity of the VLP preparation and thus cause safety concerns and regulatory complications. However, previous studies have shown that residual baculovirus in baculovirus-derived VLPs can enhance immunogenicity by activating the innate immune response [44]. As long as the crude VLPs are only employed for veterinary use, these residual baculovirus may exhibit significant adjuvant activity without causing safety concerns.

In addition, since a major challenge is to develop cost-effective production platforms that can express VLPs while significantly reducing production times and costs, robust and flexible production platforms are emerging to produce a range of VLPs targeting different viruses. For example, commercial VLP production has been achieved with *Escherichia coli*, yeast, baculovirus-insect cell expression systems, and CHO mammalian cell expression systems [45]. As shown in Table 1, only the baculovirus-insect cell expression system has been used
for the production of influenza VLPs for veterinary use, as insect cells can readily co-express multiple proteins and assemble them into structurally complex VLPs. Both E. coli and yeast offer high yields and ease of scale-up, with the yeast expression system providing for post-translational modification. Thus, for cost-effective VLP production, expression of VLPs using alternative systems such as yeasts and plants for large-scale production need to be explored.

Stimulating the innate immune system is important for inducing potent adaptive immunity. Viruses can interact with innate immune system through pattern recognition receptors such as TLR and thus are highly effective at inducing adaptive immune responses. Incorporation of immunostimulatory molecules including TLR agonists into VLP antigens would enhance the immunogenicity of influenza VLPs and thus produce dose-sparing effects and broader cross-protection [37]. Up until now, several immunostimulatory molecules have been evaluated as molecular adjuvants for VLPs for human viruses, but this approach has not yet been tried for the development of veterinary VLP vaccines. In addition, chimeric influenza VLP antigens, which are composed of HA protein hetero-subtypes or immunogenic proteins from different virus, have been developed [8,46]. In particular, a chimeric VLP vaccine that contained M1 and HA from AIV and a chimeric protein containing the cytoplasmic and transmembrane domains of NA from AIV and the ectodomain of the HA-NA protein from NDV induced antibody responses against both AIV and NDV [8]. In terms of cost-effectiveness and broad cross-protectivity, the incorporation of molecular adjuvant and heterologous epitopes into VLP antigens could be promising strategies for the development of VLP vaccines for veterinary use.

In conclusion, VLPs can be considered to provide an innovative influenza vaccine platform in the veterinary field that both induces protective immune responses against animal influenza viruses and has a solid safety profile. In addition, VLP vaccines may be useful in DIVA strategies and so are more attractive than whole viruses for vaccine development in the veterinary field. However, there are technical and practical considerations that may limit the application of VLP vaccines. Production cost is an important issue that influences the feasibility of VLP vaccines in veterinary use. Thus, development of large-scale production platform using various systems is required for cost-effective VLP production. Further, the development of VLPs as a platform for the co-expression of molecular adjuvants or foreign antigens can broaden their potential applicability. Overall, an amalgamation of bioengineering and chimeric VLP technologies will accelerate the development and application of new generation influenza VLP vaccines for veterinary use.

ORCID

Dong-Hun Lee  http://orcid.org/0000-0002-0820-7378
Jae-Keun Park  http://orcid.org/0000-0002-3367-1770
Chang-Seon Song  http://orcid.org/0000-0002-4158-6402

References

1. Sandrock C, Kelly T. Clinical review: update of avian influenza A infections in humans. Crit Care 2007;11:209.
2. Lee NH, Lee JA, Park SY, Song CS, Choi IS, Lee JB. A review of vaccine development and research for industry animals in Korea. Clin Exp Vaccine Res 2012;1:18-34.
3. Lee DH, Bae SW, Park JK, et al. Virus-like particle vaccine protects against H3N2 canine influenza virus in dog. Vaccine 2013;31:3268-73.
4. Lee DH, Park JK, Lee YN, et al. H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals. Vaccine 2011;29:4003-7.
5. Park JK, Lee DH, Youn HN, et al. Protective efficacy of crude virus-like particle vaccine against HPAI H5N1 in chickens and its application on DIVA strategy. Influenza Other Respir Viruses 2013;7:340-8.
6. Prel A, Le Gall-Recule G, Jestin V. Achievement of avian influenza virus-like particles that could be used as a sub-unit vaccine against low-pathogenic avian influenza strains in ducks. Avian Pathol 2008;37:513-20.
7. Pyo HM, Masic A, Woldeab N, et al. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs. Vaccine 2012;30:1297-304.
8. Shen H, Xue C, Lv L, et al. Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease. Virus Res 2013;178:430-6.
9. Fields BN, Knipe DM, Howley PM. Fields virology. 6th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2013.
10. Nayak B, Kumar S, DiNapoli JM, et al. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J Virol 2010;84:2408-20.
11. Alexander DJ. An overview of the epidemiology of avian influenza. Vaccine 2007;25:5637-44.
12. Saif YM, Fadly AM, Glisson JR, McDougald LR, Nolan LK, Swayne DE. Diseases of poultry. 12th ed. Ames: Blackwell Publishing; 2008.
13. Butler D. Vaccination will work better than culling, say bird flu experts. Nature 2005;434:810.
14. Swayne DE, Spackman E. Current status and future needs in diagnostics and vaccines for high pathogenicity avian influenza. Dev Biol (Basel) 2013;135:79-94.
15. Naeem K, Siddique N, Ayaz M, Jalalee MA. Avian influenza in Pakistan: outbreaks of low- and high-pathogenicity avian influenza in Pakistan during 2003-2006. Avian Dis 2007;51(1 Suppl):189-93.
16. Perk S, Panshin A, Shihmanter E, et al. Ecology and molecular epidemiology of H9N2 avian influenza viruses isolated in Israel during 2000-2004 epizootic. Dev Biol (Basel) 2006;124:201-9.
17. Wu R, Sui ZW, Zhang HB, et al. Characterization of a pathogenic H9N2 influenza A virus isolated from central China in 2007. Arch Virol 2008;153:1549-55.
18. Zimmerman JJ, Karriker LA, Ramirez A, Schwartz KJ, Stevenson GW. Diseases of swine. 10th ed. Chichester: Wiley-Blackwell; 2012.
19. Ma W, Kahn RE, Richt JA. The pig as a mixing vessel for influenza viruses: Human and veterinary implications. J Mol Genet Med 2008;3:158-66.
20. Thacker E, Janke B. Swine influenza virus: zoonotic potential and vaccination strategies for the control of avian and swine influenzas. J Infect Dis 2008;197 Suppl 1:S19-24.
21. Houser RE, Heuschele WP. Evidence of prior infection with influenza A/Texas/77 (H3N2) virus in dogs with clinical parainfluenza. Can J Comp Med 1980;44:396-402.
22. Gibbs EP, Anderson TC. Equine and canine influenza: a review of current events. Anim Health Res Rev 2010;11:43-51.
23. Songserm T, Amornsin A, Jam-on R, et al. Fatal avian influenza A H5N1 in a dog. Emerg Infect Dis 2006;12:1744-7.
24. Lin D, Sun S, Du L, et al. Natural and experimental infection of dogs with pandemic H1N1/2009 influenza virus. J Gen Virol 2012;93(Pt 1):119-23.
25. Newton R, Cooke A, Elton D, et al. Canine influenza virus: cross-species transmission from horses. Vet Rec 2007;161:142-3.
26. Li S, Shi Z, Jiao P, et al. Avian-origin H3N2 canine influenza A viruses in Southern China. Infect Genet Evol 2010;10:1286-8.
27. Song D, Lee C, Kang B, et al. Experimental infection of dogs with avian-origin canine influenza A virus (H3N2). Emerg Infect Dis 2009;15:56-8.
28. Lee YN, Lee HJ, Lee DH, et al. Severe canine influenza in dogs correlates with hyperchemokinemia and high viral load. Virology 2011;417:57-63.
29. Deshpande MS, Jirjis FF, Tubbs AL, et al. Evaluation of the efficacy of a canine influenza virus (H3N8) vaccine in dogs following experimental challenge. Vet Ther 2009;10:103-12.
30. Lee C, Jung K, Oh J, et al. Protective efficacy and immunogenicity of an inactivated avian-origin H3N2 canine influenza vaccine in dogs challenged with the virulent virus. Vet Microbiol 2010;143:184-8.
31. Belshe RB. Current status of live attenuated influenza virus vaccine in the US. Virus Res 2004;103:177-85.
32. Kang SM, Pushko P, Bright RA, Smith G, Compans RW. Influenza virus-like particles as pandemic vaccines. Curr Top Microbiol Immunol 2009;333:269-89.
33. Haynes JR. Influenza virus-like particle vaccines. Expert Rev Vaccines 2009;8:435-45.
34. Kang SM, Kim MC, Compans RW. Virus-like particles as universal influenza vaccines. Expert Rev Vaccines 2012;11:995-1007.
35. Song H, Wittman V, Byers A, et al. In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. Vaccine 2010;28:5524-32.
36. Hemann EA, Kang SM, Legge KL. Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination. J Immunol 2013;191:2486-94.
37. Wang BZ, Quan FS, Kang SM, Bozza J, Skountzou I, Compans RW. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 2008;82:11813-23.
38. Crisci E, Barcena J, Montoya M. Virus-like particles: the new frontier of vaccines for animal viral infections. Vet Immunol Immunopathol 2012;148:211-25.
39. Liu F, Ge S, Li L, Wu X, Liu Z, Wang Z. Virus-like particles: potential veterinary vaccine immunogens. Res Vet Sci 2012;93:553-9.
40. Prelu A, Le Gall-Recule G, Cherbonnel M, Grasland B, Amelot M, Jestin V. Assessment of the protection afforded by tri-
ple baculovirus recombinant coexpressing H5, N3, M1 proteins against a homologous H5N3 low-pathogenicity avian influenza virus challenge in Muscovy ducks. Avian Dis 2007;51(1 Suppl):484-9.

41. Suarez DL. Overview of avian influenza DIVA test strategies. Biologicals 2005;33:221-6.

42. Meeusen EN, Walker J, Peters A, Pastoret PP, Jungersen G. Current status of veterinary vaccines. Clin Microbiol Rev 2007;20:489-510

43. Maeda S. Construction of recombinant baculoviruses carrying insect selective neurotoxin genes for pest insect control. Tanpakushitsu Kakusan Koso 1992;37:842-7.

44. Margine I, Martinez-Gil L, Chou YY, Krammer F. Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity. PLoS One 2012;7:e51559.

45. Lua LH, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg AP. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng 2014;111:425-40.

46. Pushko P, Pearce MB, Ahmad A, et al. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 2011;29:5911-8.